Scotland's cost regulator rejects Vertex cystic fibrosis dru...

Scotland’s cost-effectiveness body has rejected regular NHS funding for Vertex’s cystic fibrosis drugs Orkambi and Symkevi because of concerns about whether their high costs justify uncerta

Vertex presses go on its cystic fibrosis triple filing

Orkambi parents start ‘buyers club’ to import generic versio...

A group of parents in the UK have taken matters into their own hands in an effort to get their children access to Orkambi, the cystic fibrosis drug at the centre of a three and a half year

Vertex selects its triple for cystic fibrosis

Vertex Pharma has chosen the three-drug combination it intends to submit for approval later this year for cystic fibrosis, in a bid to add another product to its stable.

NHS England improves offer to Vertex over CF drugs

NHS officials in England have made an improved two-year pricing deal to Vertex Pharmaceuticals in a bid to give patients access to cystic fibrosis (CF) medicines.

Health secretary hints at 'constructive' talks over CF drugs

Health secretary Matt Hancock has offered hope to thousands of people in the UK who have been denied access to powerful cystic fibrosis drugs because of a row over pricing with manufacturer